降低粪便免疫化学试验异常截断值可提高系统级筛查中结直肠癌检出
前瞻性研究纳入17017例50至64岁未参保、筛查未达标的患者,将粪便免疫化学试验异常截断值从≥20 μg血红蛋白/g粪便降至≥10 μg/g。降低截断值使异常结果比例从6.6%升至12.3%,晚期肿瘤检出率10.2% vs 12.7%无显著差异,但需结肠镜人数增加。作者认为若结肠镜资源允许,可考虑降低截断值。
要点
- 降低截断值使异常FIT比例从6.6%升至12.3%(P=0.0013),结肠镜需求约翻倍。
- 晚期肿瘤检出率降低阈值10.2% vs 标准阈值12.7%(P=0.12),无显著差异。
- 72.7%的CRC和67.3%的晚期腺瘤患者血红蛋白≥20 μg/g粪便。
核心结论
- 在17017例未参保患者的前瞻性研究中,将异常FIT截断值降至≥10 μg血红蛋白/g粪便可能增加晚期肿瘤检出,但需诊断性结肠镜的患者比例翻倍。
- 作者认为若结肠镜容量允许,使用定量FIT的卫生系统可考虑降低异常截断值以优化CRC检出和预防。
研究设计与样本
- 前瞻性研究,纳入17017例50至64岁、筛查未达标的未参保患者,来自德克萨斯州安全网系统,邮寄外展项目。
- 将异常FIT截断值预先从≥20降至≥10 μg血红蛋白/g粪便;所有FIT异常者接受免费诊断性结肠镜;5838人完成FIT。
主要发现
- FIT异常比例:≥10 μg/g组12.3% vs ≥20 μg/g组6.6%(P=0.0013)。
- 晚期肿瘤检出率:降低阈值10.2% vs 标准阈值12.7%(P=0.12);CRC检出率0.9% vs 1.2%(P=0.718)。
- 阳性预测值:晚期肿瘤降低阈值18.9% vs 标准阈值24.4%(P=0.053);CRC 1.7% vs 2.4%(P=0.659)。
- 筛查需数(NNS)检出1例晚期肿瘤:降低阈值45 vs 标准阈值58;结肠镜需数(NNS)从4增至5。
- 10–19 μg/g组中,3例CRC(3/11;27.3%)和36例晚期腺瘤(36/110;32.7%)在标准阈值下不会被检出(晚期肿瘤比较P<0.001);FIT异常后无肿瘤比例(假阳性)降低阈值44.4% vs 标准阈值39.1%(P=0.1103),无显著差异。
关键数值与推荐
- 异常FIT截断值:降低阈值≥10 μg血红蛋白/g粪便,标准阈值≥20 μg血红蛋白/g粪便。
- 多数CRC(72.7%)和晚期腺瘤(67.3%)患者血红蛋白≥20 μg/g粪便。
临床怎么用
- 作者认为若结肠镜容量允许,使用定量FIT的卫生系统可考虑将异常截断值降至≥10 μg血红蛋白/g粪便以优化CRC检出和预防。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Noninvasive tests used in colorectal cancer screening, such as the fecal immunochemical test (FIT), are more acceptable but detect neoplasias with lower levels of sensitivity than colonoscopy. We investigated whether lowering the cut-off concentration of hemoglobin for designation as an abnormal FIT result increased the detection of advanced neoplasia in a mailed outreach program. METHODS: We performed a prospective study of 17,017 uninsured patients, age 50 to 64 years, who were not current with screening and enrolled in a safety-net system in Texas. We reduced the cut-off value for an abnormal FIT result from 20 or more to 10 or more μg hemoglobin/g feces a priori. All patients with abnormal FIT results were offered no-cost diagnostic colonoscopy. We compared proportions of patients with abnormal FIT results and neoplasia yield for standard vs lower cut-off values, as well as absolute hemoglobin concentration distribution among 5838 persons who completed the FIT. Our primary aim was to determine the effects of implementing a lower hemoglobin concentration cut-off value on colonoscopy demand and yield, specifically colorectal cancer (CRC) and advanced neoplasia detection, compared with the standard, higher, hemoglobin concentration cut-off value. RESULTS: The proportions of patients with abnormal FIT results were 12.3% at the 10 or more μg hemoglobin/g feces and 6.6% at the standard 20 or more μg hemoglobin/g feces cut-off value (P = .0013). Detection rates for the lower vs the standard threshold were 10.2% vs 12.7% for advanced neoplasia (P = .12) and 0.9% vs 1.2% for CRC (P = .718). The positive predictive values were 18.9% for the lower threshold vs 24.4% for the standard threshold for advanced neoplasia (P = .053), and 1.7% vs 2.4% for CRC (P = .659). The number needed to screen to detect 1 case with advanced neoplasia was 45 at the lower threshold compared with 58 at the standard threshold; the number needed to scope to detect 1 case with advanced neoplasia increased from 4 to 5. Most patients with CRC (72.7%) or advanced adenoma (67.3%) had hemoglobin concentrations of 20 or more μg/g feces. In the group with 10 to 19 μg hemoglobin/g feces, there were 3 patients with CRC (3 of 11; 27.3%) and 36 with advanced adenoma (36 of 110; 32.7%) who would not have been detected at the standard positive threshold (advanced neoplasia Pcomparison < .001). The proportion of patients found to have no neoplasia after an abnormal FIT result (false positives) was not significantly higher with the lower cut-off value (44.4%) than the standard cut-off value (39.1%) (P = .1103). CONCLUSIONS: In a prospective study of 17,017 uninsured patients, we found that reducing the abnormal FIT result cut-off value (to ≥10 μg hemoglobin/g feces) might increase detection of advanced neoplasia, but doubled the proportion of patients requiring a diagnostic colonoscopy. If colonoscopy capacity permits, health systems that use quantitative FITs should consider lowering the abnormal cut-off value to optimize CRC detection and prevention. (ClinicalTrials.gov no: NCT01946282.).
引用
- Berry E, Miller S, Koch M, et al. Lower Abnormal Fecal Immunochemical Test Cut-Off Values Improve Detection of Colorectal Cancer in System-Level Screens. Clin Gastroenterol Hepatol. 2019. PMID: 31085338. doi:10.1016/j.cgh.2019.04.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。